MX2022010299A - Derivados macrocíclicos de indol como inhibidores de mcl-1. - Google Patents

Derivados macrocíclicos de indol como inhibidores de mcl-1.

Info

Publication number
MX2022010299A
MX2022010299A MX2022010299A MX2022010299A MX2022010299A MX 2022010299 A MX2022010299 A MX 2022010299A MX 2022010299 A MX2022010299 A MX 2022010299A MX 2022010299 A MX2022010299 A MX 2022010299A MX 2022010299 A MX2022010299 A MX 2022010299A
Authority
MX
Mexico
Prior art keywords
mcl
inhibitors
indole derivatives
macrocyclic indole
macrocyclic
Prior art date
Application number
MX2022010299A
Other languages
English (en)
Inventor
Adriana Ingrid Velter
Frederik Jan Rita Rombouts
Tristan Reuillon
Ann Marleen Vos
Aldo Peschiulli
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022010299A publication Critical patent/MX2022010299A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o la profilaxis en un sujeto, una composición farmacéutica que comprende tales compuestos y su uso como inhibidores de MCL-1, útiles para tratar enfermedades tales como el cáncer.
MX2022010299A 2020-02-21 2021-02-18 Derivados macrocíclicos de indol como inhibidores de mcl-1. MX2022010299A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20158764 2020-02-21
EP20169887 2020-04-16
EP20184956 2020-07-09
PCT/EP2021/053973 WO2021165370A1 (en) 2020-02-21 2021-02-18 Macrocyclic indole derivatives as inhibitors of mcl-1

Publications (1)

Publication Number Publication Date
MX2022010299A true MX2022010299A (es) 2022-11-14

Family

ID=74626012

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010299A MX2022010299A (es) 2020-02-21 2021-02-18 Derivados macrocíclicos de indol como inhibidores de mcl-1.

Country Status (10)

Country Link
US (1) US20230130109A1 (es)
EP (1) EP4107161A1 (es)
JP (1) JP2023514364A (es)
KR (1) KR20220143906A (es)
CN (1) CN115151551B (es)
AU (1) AU2021222332A1 (es)
BR (1) BR112022016444A2 (es)
CA (1) CA3168355A1 (es)
MX (1) MX2022010299A (es)
WO (1) WO2021165370A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3200758A1 (en) * 2020-12-17 2022-06-23 Janssen Pharmaceutica Nv Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
JP6894449B2 (ja) * 2016-04-22 2021-06-30 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 癌を治療するためのマクロ環状ｍｃｌ１阻害剤
TW201904976A (zh) * 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法
TWI781996B (zh) 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成ｍｃｌ-１抑制劑之方法
US20220041623A1 (en) * 2018-09-30 2022-02-10 Jiangsu Hengrui Medicine Co., Ltd. Indole macrocyclic derivative, preparation method thereof and application thereof in medicine
EP3781570A4 (en) 2018-11-22 2021-06-02 Ascentage Pharma (Suzhou) Co., Ltd. MACROCYCLIC INDOLES SERVING AS MCL-1 INHIBITORS
WO2020151738A1 (en) * 2019-01-23 2020-07-30 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic fused pyrrazoles as mcl-1 inhibitors
EP3924358A4 (en) * 2019-03-08 2023-07-05 Zeno Management, Inc. Macrocyclic compounds
ES2975083T3 (es) * 2019-06-21 2024-07-03 Janssen Pharmaceutica Nv Inhibidores macrocíclicos de MCL-1

Also Published As

Publication number Publication date
AU2021222332A1 (en) 2022-10-20
CN115151551B (zh) 2024-10-25
KR20220143906A (ko) 2022-10-25
JP2023514364A (ja) 2023-04-05
CA3168355A1 (en) 2021-08-26
WO2021165370A1 (en) 2021-08-26
CN115151551A (zh) 2022-10-04
US20230130109A1 (en) 2023-04-27
BR112022016444A2 (pt) 2022-10-18
EP4107161A1 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
SA523440916B1 (ar) Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EA202191801A1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
ZA202403388B (en) Small molecules for treatement of cancer
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
ZA202003554B (en) 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
MX2023008677A (es) Derivados de urolitinas y métodos para su uso.
MX2025008920A (es) Inhibidores de parp1 triciclicos y usos de estos
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX393711B (es) Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres
PH12020500666A1 (en) Pladienolide compounds and their use
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX389786B (es) Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.
MX2024004874A (es) Compuestos heterociclicos para uso en el tratamiento de cancer.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
MX2022010299A (es) Derivados macrocíclicos de indol como inhibidores de mcl-1.
MX2022015005A (es) Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1.
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
MX2024005928A (es) 2-amino-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MX2022016004A (es) Desderivados de 7-(pirazol-5-il)-indol macrociclicos enlazados a n como inhibidores de mcl-1.
MX2022015998A (es) Derivados de 4-(pirazol-5-il)-indol macrocíclico unidos a n como inhibidores de mcl-1.
MX2023007291A (es) Derivados de 4-(pirazol-5-il)-indol macrociclicos ramificados como inhibidores de mcl-1.